These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 31729990)

  • 1. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.
    Pratley RE; Husain M; Lingvay I; Pieber TR; Mark T; Saevereid HA; Møller DV; Zinman B;
    Cardiovasc Diabetol; 2019 Nov; 18(1):156. PubMed ID: 31729990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
    Wysham C; Bhargava A; Chaykin L; de la Rosa R; Handelsman Y; Troelsen LN; Kvist K; Norwood P
    JAMA; 2017 Jul; 318(1):45-56. PubMed ID: 28672317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
    Marso SP; McGuire DK; Zinman B; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Haahr PM; Lange M; Brown-Frandsen K; Moses A; Skibsted S; Kvist K; Buse JB;
    N Engl J Med; 2017 Aug; 377(8):723-732. PubMed ID: 28605603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.
    Lane W; Bailey TS; Gerety G; Gumprecht J; Philis-Tsimikas A; Hansen CT; Nielsen TSS; Warren M; ;
    JAMA; 2017 Jul; 318(1):33-44. PubMed ID: 28672316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).
    Pollock RF; Heller S; Pieber TR; Woo V; Gundgaard J; Hallén N; Luckevich M; Tutkunkardas D; Zinman B;
    Diabetes Obes Metab; 2019 Jul; 21(7):1706-1714. PubMed ID: 30924579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2.
    Heller SR; DeVries JH; Wysham C; Hansen CT; Hansen MV; Frier BM
    Diabetes Obes Metab; 2019 Jul; 21(7):1634-1641. PubMed ID: 30891886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).
    Pratley RE; Emerson SS; Franek E; Gilbert MP; Marso SP; McGuire DK; Pieber TR; Zinman B; Hansen CT; Hansen MV; Mark T; Moses AC; Buse JB;
    Diabetes Obes Metab; 2019 Jul; 21(7):1625-1633. PubMed ID: 30850995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).
    Zinman B; Marso SP; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Lange M; Brown-Frandsen K; Moses A; Ocampo Francisco AM; Barner Lekdorf J; Kvist K; Buse JB;
    Diabetologia; 2018 Jan; 61(1):48-57. PubMed ID: 28913575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality.
    Pieber TR; Marso SP; McGuire DK; Zinman B; Poulter NR; Emerson SS; Pratley RE; Woo V; Heller S; Lange M; Brown-Frandsen K; Moses A; Barner Lekdorf J; Lehmann L; Kvist K; Buse JB;
    Diabetologia; 2018 Jan; 61(1):58-65. PubMed ID: 28913543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1.
    Marso SP; McGuire DK; Zinman B; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Haahr PM; Lange M; Frandsen KB; Rabøl R; Buse JB
    Am Heart J; 2016 Sep; 179():175-83. PubMed ID: 27595693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12).
    Amod A; Buse JB; McGuire DK; Pieber TR; Pop-Busui R; Pratley RE; Zinman B; Hansen MB; Jia T; Mark T; Poulter NR;
    Diab Vasc Dis Res; 2020; 17(6):1479164120970933. PubMed ID: 33280425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial.
    Tarride JE; Husain M; Andersen A; Gundgaard J; Luckevich M; Mark T; Wagner L; Pieber TR
    J Med Econ; 2021; 24(1):1318-1326. PubMed ID: 34763587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Outcomes Trials Update: Insights from the DEVOTE Trial.
    Bilal A; Pratley RE
    Curr Diab Rep; 2018 Sep; 18(11):102. PubMed ID: 30229352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).
    Pollock RF; Valentine WJ; Marso SP; Andersen A; Gundgaard J; Hallén N; Tutkunkardas D; Magnuson EA; Buse JB;
    Appl Health Econ Health Policy; 2019 Oct; 17(5):615-627. PubMed ID: 31264138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials.
    Zhang XW; Zhang XL; Xu B; Kang LN
    Acta Diabetol; 2018 May; 55(5):429-441. PubMed ID: 29423761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.
    DeVries JH; Bailey TS; Bhargava A; Gerety G; Gumprecht J; Heller S; Lane W; Wysham CH; Zinman B; Bak BA; Hachmann-Nielsen E; Philis-Tsimikas A
    Diabetes Obes Metab; 2019 Mar; 21(3):622-630. PubMed ID: 30362250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing, Planning and Conducting an Interim Analysis: Lessons From the DEVOTE Cardiovascular Outcomes Trial (Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events).
    Theilgaard H; Mollerup I; Helmark IC; Endahl L; Hoskin S; Hvelplund A; Amby LK; Moses AC
    Ther Innov Regul Sci; 2019 Mar; 53(2):279-286. PubMed ID: 29793353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
    Russel-Szymczyk M; Valov V; Savova A; Manova M
    BMC Endocr Disord; 2019 Dec; 19(1):132. PubMed ID: 31796048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia.
    Heller S; Mathieu C; Kapur R; Wolden ML; Zinman B
    Diabet Med; 2016 Apr; 33(4):478-87. PubMed ID: 26484727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100.
    Alexopoulos AS; Andersen A; Donatsky AM; Gowda A; Buse JB
    Diabetes Obes Metab; 2021 Aug; 23(8):1983-1988. PubMed ID: 33830626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.